Two programmes created in the early 1990s with the intention of helping consumers pay for their prescribed medications are expected to expand substantially in 2024.
A proposal by the US Department of Health and Human Services (HHS) would expose the actual costs of drugs covered by Medicaid, and hold manufacturers to account for the am